Status:
WITHDRAWN
Evaluation of Two Different Treatments for Lower Pore Renal Stone: Microperc Vs FURS
Lead Sponsor:
Ningbo No. 1 Hospital
Collaborating Sponsors:
Beijing Friendship Hospital
Renmin Hospital of Wuhan University
Conditions:
Surgery--Complications
Renal Calculus
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
This is a prospect, randomized control trial to evaluate merits between microperc and FURS for lower pole renal stone
Detailed Description
To evaluate the merits of Microperc and RIRS for the treatment for lower pole renal stone between 10-20 mm. Investigators will do a multi-centers randomized controlled trial(RCT). A total of 200 (thre...
Eligibility Criteria
Inclusion
- 10-20mm lower pole renal stone measured by KUB or CT;
- Age between 18-60 years, no gender limitation;
- Participators can understand the research and sign the consent form without mental illness nor language disorder;
- Low pole renal stone left after lithotripsy;
- Lower pole infundibulopelvic angle which measured by IVP or CTU will less than 30 degree;
- Asymptomatic patients with positive urine white blood cells and negative preoperative urine culture should be treated with antibiotics for 3days before operation;
- Patients with symptoms of urinary infections, positive urine withe blood cells and positive preoperative urine culture should be treated with suitable antibiotics based on the culture sensitivity result for at least 7days before operation.
Exclusion
- Transplant kidney stone;
- Renal malformations, such as UPJO, medullary sponge kidney, polycystic kidney, horseshoe kidney, etc.;
- Combine other part of urinary stones need to be handle at the same procedure, for example ureteral stone, renal pelvic stone, middle or upper pole renal stone;
- Hematological Disease or Coagulation disorders;
- Withdraw anticoagulant medicine less than two weeks;
- Fever or urinary infections without treatment according to the inclusion criteria;
- Sevier renal dysfunction(endogenous creatinine clearance rate≤50ml/min)
- Middle or severe hydronephrosis(dilatation of the renal pelvis ≥20mm by ultrasound);
- Women in menstrual period or pregnancy;
- Patients have severe disease, such as heart disease, lung dysfunction, and multiple organ failure that cannot tolerate anesthesia or operation.
Key Trial Info
Start Date :
November 17 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03307096
Start Date
November 17 2017
End Date
December 31 2019
Last Update
July 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ningbo NO.1 hospital
Ningbo, Zhejiang, China, 315010